Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders

Keyphrases

• Infliximab 100%
• Inflammatory Disorders 100%
• Biological Agents 100%
• Adalimumab 100%
• Anti-tumor Necrosis Factor (anti-TNF) 100%
• Expert Panel Recommendations 100%
• Immunosuppressive Agents 60%
• Uveitis 60%
• Immunomodulation 40%
• Inflammatory Eye Disease 40%
• Inflammatory Conditions 40%
• Low Dose Rate 20%
• Etanercept 20%
• Clinical Significance 20%
• Scleritis 20%
• Calcineurin Inhibitors 20%
• Treatment Efficacy 20%
• Systematic Literature Review 20%
• Controlled Experiment 20%
• Expert Panel 20%
• Ocular Manifestations 20%
• Vision Loss 20%
• Panuveitis 20%
• Rheumatologic Diseases 20%
• Antimetabolites 20%
• Behet's Disease 20%
• Evaluation Assessment 20%
• Assessment Development 20%
• Grading of Recommendations 20%
• Posterior Uveitis 20%
• Seronegative Spondyloarthropathy 20%
• Systemic Juvenile Idiopathic Arthritis (sJIA) 20%
• Anti-tumor Necrosis Factor Agents 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Disease 100%
• Tumor Necrosis Factor 100%
• Biological Product 100%
• Uveitis 100%
• Infliximab 100%
• Adalimumab 100%
• Inflammation 40%
• Immunomodulation 40%
• Inflammatory Disease 40%
• Etanercept 20%
• Controlled Clinical Trial 20%
• Visual Impairment 20%
• Scleritis 20%
• Antimetabolite 20%
• Calcineurin Inhibitor 20%
• Tumor Necrosis Factor Inhibitor 20%
• Spondyloarthropathy 20%
• Juvenile Rheumatoid Arthritis 20%

Immunology and Microbiology

• Tumor Necrosis Factor 100%
• Biological Product 100%
• Inflammatory Disorder 100%
• Uveitis 100%
• Infliximab 100%
• Adalimumab 100%
• Immunomodulation 40%
• Etanercept 20%
• Scleritis 20%
• TNF Inhibitor 20%
• Juvenile Idiopathic Arthritis 20%